

## **Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through structure based drug design**

Hengmiao Cheng,<sup>\*a</sup> Chunze Li,<sup>b</sup> Simon Bailey,<sup>a</sup> Sangita M. Baxi,<sup>c</sup> Lance Goulet,<sup>b</sup> Lisa Guo,<sup>a</sup> Jacqui Hoffman,<sup>a</sup> Ying Jiang,<sup>b</sup> Theodore Otto Johnson,<sup>a</sup> Ted W. Johnson,<sup>a</sup> Daniel R. Knighton,<sup>a</sup> John Li,<sup>c</sup> Kevin Liu,<sup>a</sup> Zhengyu Liu,<sup>a</sup> Matthew A. Marx,<sup>a</sup> Marlena Walls,<sup>c</sup> Peter A. Wells,<sup>c</sup> Min-Jean Yin,<sup>c</sup> Jingjiang Zhu,<sup>a</sup> Michael Zientek,<sup>b</sup>

<sup>a</sup> Cancer Chemistry, Pfizer Worldwide Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, CA, 92121, USA

<sup>b</sup> PDM, Pfizer Worldwide Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, CA, 92121, USA

<sup>c</sup> Oncology Research Unit, Pfizer Worldwide Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, CA, 92121, USA

\*Corresponding author: [henry.cheng@pfizer.com](mailto:henry.cheng@pfizer.com)

### Supplemental Material Section

Invitrogen KSS data, % inhibition at 1  $\mu$ M of PF-04979064 tested at ATP concentration =  $K_m$ , average of n=4:

STK6: 1.00%  
CDK2: 0.50%  
CHEK1: 7.75%  
CHEK2: 1.50%  
SRC: 8.25%  
EGFR: -1.50%  
EPHA2: 1.50%  
FGFR: -1.00%  
GSK3 $\beta$ : 0.500%  
INSR: 7.50%  
JAK3: 1.75%  
KDR: 8.25%  
LCK1: 7.75%  
MAPK1: 2.00%  
MAPKAPK2: -0.250%  
MARK1: -1.00%  
MET: 3.25%  
STK3: 8.00%  
NEK2: 0.25%  
PAK4: -2.00%  
PIM2: 1.25%  
AKT1: -3.0%  
ROCK1: 5.25%  
SGK: -1.75%  
TEK: 5.75%  
NTRK1: 9.25%  
TAOK2: 2.25%  
CAMK2A: 6.75%  
CSNK1A1: 9.50%  
CSNK2A2: 3.0%  
MAP4K4: 22.8%  
MST4: -2.00%  
MYLK2: 0.750%  
PRKCB2: 0.250%  
PDK1: 7.25%  
P28: 3.25%